PD-L1 checkpoint inhibitor (Jiangsu Hyamab Pharmaceutical)

N/A

Report date: 2025/03/20 15:38:14

Base Information

Drug NamePD-L1 checkpoint inhibitor (Jiangsu Hyamab Pharmaceutical)
Drug Alias Nameanti-PD-L1 fully human monoclonal antibody (Jiangsu Hyamab Pharmaceutical)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Huaiyu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Huaiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A